ABBV | AlphaStreet

Abbvie’s oncology push makes it an attractive stock

Abbvie (NYSE: ABBV) is one of the worse performing pharma stocks in the trailing 12-month period. The stock has declined almost 19%

AbbVie Inc. (NYSE: ABBV) surpassed market estimates on revenue and earnings for the first quarter of 2019, giving shares a lift of

The general market sentiment on Merck & Co. (MRK) is quite bullish ahead of the drug maker’s fourth-quarter earnings report. Analysts predict

AbbVie Inc. (ABBV) slipped to a loss in the fourth quarter from a profit last year, due to the inclusion of the

A slew of major companies are reporting earnings this week. Healthcare giant Johnson & Johnson (JNJ) will announce fourth-quarter earnings on Tuesday

US pharma giant AbbVie Inc (ABBV) cut its overseas sales forecast on Friday for its offering Humira, on expected pricing cuts to

AbbVie Inc. (ABBV) reported a 68% jump in earnings for the third quarter helped by sales growth from Humira, Imbruvica, and HCV.